miR-200家族作为卵巢癌预后标志物的meta分析

目的:系统评价mi R-200家族(mi R-200a、mi R-200b、mi R-200c、mi R-141、mi R-429)的表达与卵巢癌预后之间的关系。方法:仔细检索搜索美国国立图书馆(Pub Med),荷兰医学文摘(EMBASE)以及ISI Web of Science、CNKI、万方等数据库,与mi R-200家族相关的卵巢癌预后的文献。检索日期为数据库的建库时间至2013年9月20日。提取与mi R-200家族相关卵巢癌预后的相应数据,应用Stata11.0软件进行Meta分析。结果:共有7篇研究符合入选标准,累积肿瘤组织577例。Meta分析显示,mi R-200家族低表达组的合并优势比是高表达组的1.347倍(95%CI:1.052,1.725)。mi R-200a、mi R-200c、mi R-141的亚组分析结果分别为1.091(95%CI:0.718,1.659)、1.285(95%CI:0.765,2.161),1.122(95%CI:1.043-1.208)。mi R-200家族、mi R-141与卵巢癌的预后之间的关系有统计学意义(P=0.018,P=0.002)。结论:mi R-200家族在卵巢癌的预后判断中可能起到预后标记物的作用。     

人附睾蛋白4在卵巢癌中的应用进展

卵巢癌是妇科常见的恶性肿瘤,其死亡率居妇科恶性肿瘤之首,早期发现有助于提高患者的五年生存率。人附睾蛋白(HE4)属于蛋白酶抑制剂家族,是一种新的卵巢癌肿瘤标志物。HE4在卵巢癌组织中及患者血清中处于高表达状态。研究表明在早期诊断方面HE4比糖类抗原125(CA125)有更高的灵敏度和特异度,在疾病的治疗过程中可以预测肿瘤细胞减灭术的满意度及患者对铂类的反应,在卵巢癌的复发及预后的监测中HE4也有很大的临床应用价值。     

肺鳞癌、腺癌组织中miRNA-210表达对预后影响的初步研究

目的:探讨肺鳞癌腺癌组织中mi RNA-210表达水平对预后的影响。方法:选取我院2004年至2007年接受手术治疗的肺鳞癌腺癌患者80例,采用定量RT-PCR测定的方法 mi RNA-210在肺癌组织中的表达,并分析其与患者临床病理特点及组织类型之间的关系。结果:定量RT-PCR测定结果显示,mi RNA-210与肺鳞癌腺癌患者的无病生存期和总生存期负相关(DFS,P=0.001;OS,P=0.004)。mi RNA-210与腺癌患者淋巴结转移(P=0.018)、晚期疾病(P=0.003)及较差的预后(P=0.002)显著相关。多因素Cox分析显示mi RNA-210是腺癌患者无病生存期的独立预后因子(P0.001)。结论:肺腺癌病人肿瘤组织重mi RNA-210可能为预后的生物标志物。     

人附睾蛋白4作为卵巢癌生物标志物的初步研究

目的:探讨人附睾蛋白4(HE4)在卵巢癌组织和血清中的表达及其临床病理意义。方法:用免疫组织化学技术检测正常卵巢,卵巢良性上皮性肿瘤,交界性上皮性肿瘤和癌组织中HE4的表达,并分析其与临床分期和预后的关系;用ELISA方法检测患者血清中HE4的含量。结果:HE4在浆液性乳头状囊腺癌组织中的阳性表达率要显著高于交界性肿瘤,良性肿瘤和正常组织,而交界性肿瘤阳性表达率显著高于良性肿瘤和正常对照。HE4表达与临床分期没有显著相关性。HE4阳性患者的平均生存期、5年生存率和中位生存期均显著低于HE4阴性患者。卵巢癌和交界性肿瘤患者血清中HE4含量显著高于良性肿瘤和正常对照组。结论:HE4可能作为卵巢癌诊断和预后的组织和血清标志物。     

miRNA-27 a在心血管疾病中的作用机制

心血管疾病作为常见的临床慢性疾病是导致死亡的主要原因.微小核苷酸(microRNAs,miRNAs)作为一类长度约为19～25 nt的内源性非编码RNA,在心血管疾病的发生和发展中起着重要作用.miRNA-27 a通过调控免疫、炎症反应以及多种病理生理过程,从而参与心血管疾病的发病过程.本文对miRNA-27 a在心血...     

FAP和Rho 家族蛋白在卵巢癌侵袭迁移中的作用

目的：明确FAP 是否通过RhoA/ROCK、Rac1-GTP 通路发挥促增殖、侵袭和迁移作用。方法：用MTT 实验,Transwell 实验 和迁移实验检测FAP、RhoA/ROCK、Rac1-GTP 对卵巢癌细胞系HO-8910PM 的增殖,侵袭和迁移的影响。结果：1、MTT 法,迁移和 侵袭实验证实用Y-27632 抑制RhoA/ROCK 途径能够促进卵巢癌细胞的增殖、迁移和侵袭,与FAP 联合作用时促进作用增强。 2、MTT 法, 迁移和侵袭实验证实NSC23766 抑制Rac1 途径能够抑制卵巢癌细胞的增殖、迁移和侵袭,与FAP 联合作用使FAP 的 促进作用减弱。结论：1、RhoA/ROCK 通路抑制HO-8910PM 细胞增殖、迁移和侵袭;Rac1-GTP 促进HO-8910PM 细胞增殖、迁移 和侵袭。2、FAP不是通过RhoA/ROCK而是通过Rac1-GTP 信号通路在HO-8910PM细胞发挥促增殖、迁移和侵袭作用的。     

Nampt在卵巢癌中的研究进展

尼克酰胺磷酸核糖转移酶(Nampt)是新近发现的一种主要由内脏脂肪细胞分泌的脂肪因子,结构复杂,存在基因多态性,具有多种生理功能:通过与胰岛素受体相互作用,在不同的情况下Nampt可表现出类胰岛素样作用;在细胞质中,能够催化烟酰胺腺嘌呤二核苷酸(NAD)的生物合成;作为分泌型的细胞因子,Nampt还可以诱导多种炎性因子的表达。最近发现,Nampt在卵巢癌中高表达,其与卵巢癌的发生发展可能有密切联系,它的发现为研究卵巢癌的发病机制增加了新内容,可能为卵巢癌的治疗提供一个新的靶点。     

FAP和Rho家族蛋白在卵巢癌侵袭迁移中的作用

目的：明确FAP是否通过RhoA／ROCK、Racl-GTP通路发挥促增殖、侵袭和迁移作用。方法：用MTT实验,Transwell实验和迁移实验检测FAP、RhoA／ROCK、Racl-GTP对卵巢癌细胞系HO-8910PM的增殖,侵袭和迁移的影响。结果：1、MTT法,迁移和侵袭实验证实用Y-27632抑制RhoA／ROCK途径能够促进卵巢癌细胞的增殖、迁移和侵袭,与FAP联合作用时促进作用增强。2、MTT法,迁移和侵袭实验证实NSC23766抑制Racl途径能够抑制卵巢癌细胞的增殖、迁移和侵袭,与FAP联合作用使FAP的促进作用减弱。结论：l、RhoA／ROCK通路抑制HO一8910PM细胞增殖、迁移和侵袭;Racl-GTP促进H0—8910PM细胞增殖、迁移和侵袭。2、FAP不是通过RhoA／ROCK而是通过Racl—GTP信号通路在HO．8910PM细胞发挥促增殖、迁移和侵袭作用的。     

Maspin在卵巢癌中作用机制的体外研究

目的:检测卵巢癌细胞中Maspin对细胞增殖能力、VEGF和乙酰肝素酶Heparanase(HPA)表达的影响。方法:构建Maspin真核表达质粒,体外转染卵巢癌SKOV3细胞,磺基罗丹明B法((sulforhodamine B,SRB)检测转染后细胞增殖能力变化,细胞免疫化学及半定量逆转录聚合酶链反应(RT-PCR)方法检测VEGF和HPA的表达。结果:成功构建Maspin真核表达质粒并转染于卵巢癌细胞SKOV3后,证实转染目的基因的SKOV3-Maspin细胞中Maspin表达明显增强;转染Maspin cDNA的SKOV3细胞的体外增殖能力明显弱于转染空载体组和未转染组,而后两者之间差异无显著性;转染Maspin cDNA的SKOV3细胞中VEGF的表达明显弱于转染空载体组和未转染组,而后两者之间差异无显著性;但是HPA的表达无明显改变。结论:Maspin可能通过下调VEGF的表达抑制卵巢癌血管生成。HPA表达与卵巢癌的恶性生物学行为密切相关,但与Maspin无明显相关性。     

miRNA-21在周围神经损伤和修复中的调控作用

周围神经损伤(PNI)后miRNA-21表达发生变化,参与神经再生的调控。本文从miRNA-21对神经元、施万细胞、神经营养因子等方面的影响进行探讨,对PNI及其修复阶段miRNA-21的表达变化和可能的作用机制作一综述,将有助于我们从分子水平进一步了解PNI的病理过程,并为miRNA-21成为一种潜在的PNI的诊断标志物和治疗靶点提供基础。     

Clinical significance of the expression of miRNA-21, miRNA-31 and miRNA-let7 in patients with lung cancer

ObjectiveTo explore the expression differences of miRNA-21, miRNA-31 and miRNA-let7 between lung cancer patient and healthy people, thereby providing reference for early diagnosis of lung cancer.MethodReal-time PCR was employed to determine the expression difference between lung cancer patients (50 cases) and healthy people (24 cases). The clinical data of lung cancer patients were analyzed to explore the correlation between clinicopathological characteristics and expression level of miRNA-21, miRNA-31, miRNA-let7.ResultsThe relative expression levels of miRNA-21 and miRNA-31 in lung cancer group were obviously higher than those in healthy control group, and the relative expression level of miRNA-let7 in lung cancer group was slightly higher than that in healthy control group. Lung cancer patients with lymph node metastasis had higher expression level than those without lymph node metastasis. The ROC curve showed that the three miRNAs had clinical diagnosis efficiency for lung cancer, and the combined detection of the three miRNAs were more efficient in diagnosing lung cancer. Survival curve analysis suggested that the median survival times of patients in the miRNA-21 and miRNA-31 high expression groups were shorter than those in the low expression groups, and the median survival time of patients in miRNA-let7 high expression group was longer than that in the low expression group.ConclusionPlasma miRNA-21, miRNA-31 and miRNA-let7 may be diagnostic marker for lung cancer.     

miRNA-200b improves hepatic fibrosis induced by CCL4 by regulating toll-like receptor 4 in mice

To study the effect of miRNA-200b on hepatic fibrosis induced by CCl₄ in mice. The C59BL/6 mice were randomly divided into three groups (normal control [NC], CCLR model [Model], and CCl ₄ + miRNA-200b [miRNA]). The hepatic fibrosis was induced by CCl ₄ injected subcutaneously twice per week in Model and miRNA groups. After 6 weeks building model, the mice of miRNA group were injected the miRNA-200b from caudal vein twice per week. The mice of Model and miRNA groups were continuously fed for 3 weeks. The IL-1β, IL-6, and TNF-α concentrations of serum were measured by enzyme-linked immunosorbent assay. The hepatic tissues of difference groups were observed by hematoxylin and eosin (H&E) staining, sirius red staining, Masson staining, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay and measured toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) proteins expressions by western blot assay. The correlation between miRNA-200b and TLR4 were analyzed by dual luciferase target assay. Compared with NC group, the interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) concentrations of Model group were significantly upregulated (P < 0.05, respectively). With miRNA-200b overexpression, the IL-1β, IL-6, and TNF-α concentrations were significantly suppressed (P < 0.05, respectively). The pathologies were improved by H&E staining, sirius red staining, and Masson staining; meanwhile, the hepatic cell apoptosis rate was significantly suppressed (P < 0.05). The TLR4 and NF-κB protein expressions of miRNA group were significantly suppressed compared with the Model group (P < 0.05, respectively). By dual luciferase target assay, the TLR4 was a target gene of miRNA-200b. The miRNA-200b upregulation improved hepatic fibrosis induced by CCl ₄ via regulation of TLR4 in vivo.     

卵巢癌生物治疗的现状与进展

由于卵巢癌的早期临床症状较不明显,大部分患者就诊时就处于晚期阶段,这对其有效治疗造成了很大困难,使其成为妇科病死率最高的恶性肿瘤,一直广受关注。但目前传统的手术与放化疗方法的治疗效果不佳。近年来随着基础研究工作的不断发展与深入,生物治疗作为新的肿瘤治疗方法引起了人们的重视。生物治疗作为第四种卵巢癌的治疗模式,其采取的针对不同靶位点和靶途径的策略很大程度上促进了卵巢癌治疗的理论和实践研究。生物治疗主要是运用基因治疗、免疫治疗和重组病毒治疗的方法对患者进行治疗,基因治疗包括细胞毒性或自杀基因治疗、纠错性基因治疗、免疫增强性基因治疗和抗肿瘤血管生成基因治疗等。而免疫治疗又分为主动和被动免疫治疗,前者包括树突状细胞疫苗、自体肿瘤疫苗和分子疫苗治疗等,后者如细胞因子治疗、单克隆抗体拮抗治疗以及细胞过继免疫治疗等。上述目前在卵巢癌治疗研究中已取得了一些成果,本文就其卵巢癌的生物治疗现状与进展做一综述。     

Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review

BackgroundBreast cancer (BC) is the most common cancer for women all over the world. Great interests have been paid to discover accurate and noninvasive methods for breast cancer diagnosis and prognosis. Although the diagnostic and prognostic value of microRNA-200 (miRNA- 200, miR-200) family has been revealed in many studies, the results were inconsistent. Thus, this meta-analysis aims to assess the overall value of miRNA-200 family in breast cancer diagnosis and prognosis.MethodRelevant studies were searched from the following databases: PubMed, PMC, EMBASE, and ScienceDirect using key words: ("miRNA-200 family" or "miR-141" or "miR-200a" or "miR-200b" or "miR-200c" or "miR-429") and (“HER2” or “Luminal A” or “Luminal B” or “TNBC”) and ("breast cancers" or "breast carcinoma" or "breast malignancy" or "breast tumor"). The sensitivity, specificity, AUC were then calculated to estimate the diagnostic accuracy of the miR-200 family. As for the prognostic value of the miR-200 family, the pooled hazard ratio (HR) was assessed. Heterogeneity among individual studies was also examined by subgroup analyses.ResultA total of 24 articles were included in the meta-analysis. The diagnostic value of miR-200s in BC was presented by the pooled sensitivity was 0.86 (95% CI: 0.83-0.88); the pooled specificity was 0.82 (95% CI: 0.72-0.89); the pooled AUC was 0.931 (95% CI: 0.919-0.942). Besides, expression of miR-200s in metastatic breast cancer has sensitivity, specificity and AUC of 0.70 (95%CI: 0.56-0.81), 0.72 (95%CI: 0.61-0.81), and 0.814 (95%CI: 0.741-0.903), respectively. The meta-analysis then revealed that high expression of miR-200 family corresponded to poor OS (HR: 1.63, 95% CI: 1.03-2.52), poor DFS (HR: 1.55, 95% CI: 0.95-2.56) in BC patients while downregulation of miRNA-200s corresponded to poor OS (HR= 0.84, 95%CI: 0.46-1.63) in TNBC patients and poor OS (HR=0.49; 95%CI: 0.27-0.88) in luminal BC patient.ConclusionThe MiR-200 family has high diagnostic accuracy and can be used as an important biomarker to prognosticate breast cancer.     

人附睾蛋白4在卵巢癌中的研究进展

卵巢癌是严重威胁女性健康的恶性疾病之一。糖类抗原125（carbohydrate antigen125,CA125）是目前临床上广泛用于诊断卵巢上皮性癌的肿瘤标记物,然而其缺乏敏感性和特异性,因此,迫切需要寻找一种新的标志物来提高卵巢癌的诊断。人附睾蛋白4（human epididymis protein4,HE4）是近年发现的肿瘤标志物,其在良性肿瘤和正常组织中含量极低,但在卵巢癌中高表达。本文就HE4在卵巢癌中的诊断,动态监测等方面的进展做一综述。     

microRNA-214在恶性肿瘤中的表达及相关性的研究进展

微小RNA(microRNA,miRNA)是广泛存在于动植物中的一类不编码蛋白质的短小的单链RNA分子,一般由22个核苷酸组成,它们可以特异性地结合mRNA并通过降解或抑制其翻译而在转录后水平调控基因表达。miRNA的表达及功能可影响许多表观遗传学特征,其功能涉及细胞的发生、生长、发育、分化和凋亡过程,在肿瘤的形成和进展过程中扮演重要角色。microRNA-214(miRNA-214,miR-214)参与肝癌、乳腺癌、宫颈癌、卵巢癌、恶性黑色素瘤、胃癌、胶质瘤、儿童骨肉瘤等恶性肿瘤的发生发展,以及与肿瘤细胞的侵袭及转移密切相关。miRNA-214在不同的肿瘤中表达水平并不相同,miRNA-214在不同肿瘤中的差异表达是通过调控某个或者某些癌基因及抑癌基因而实现其参与肿瘤的发生发展、侵袭及转移的作用。因此,本文主要通过阅读大量国内外文献,总结和概括了miRNA-214参与部分恶性肿瘤发生发展的机制。虽然目前对于miRNA的理论研究已经日渐完善和成熟,但是怎样将这些研究结果应用于临床,怎样能够更准确、更便捷的通过对miRNA的检测达到对疾病的诊断、治疗以及预后评估,想必一定会成为将来研究的热点,我们期待一种新型的恶性肿瘤的分子标志物会使越来越多的肿瘤患者获益。     

人附睾蛋白4 在卵巢癌中的研究进展

卵巢癌是严重威胁女性健康的恶性疾病之一。糖类抗原125(carbohydrate antigen125,CA125)是目前临床上广泛用于诊断卵巢上皮性癌的肿瘤标记物,然而其缺乏敏感性和特异性,因此,迫切需要寻找一种新的标志物来提高卵巢癌的诊断。人附睾蛋白4(human epididymis protein 4,HE4)是近年发现的肿瘤标志物,其在良性肿瘤和正常组织中含量极低,但在卵巢癌中高表达。本文就HE4在卵巢癌中的诊断,动态监测等方面的进展做一综述。     

趋化因子SD-1及其受体CXCR4在卵巢癌中的研究进展

基质细胞衍生因子-1(Stromal cell derived factor-1,SDF-1)是CXC趋化因子家族的重要成员,系统命名为CXCL12,能与它的唯一受体CXC趋化因子受体-4(CXC chemokine receptor-4,CXCR4)形成CXCL12-CXCR4生物学轴,CXCL12-CXCR4生物学轴在肿瘤生长、侵袭、转移过程中发生重要作用。到目前为止,已发现CXCL12-CXCR4在卵巢癌、胰腺癌、肝癌等多种肿瘤组织中表达。然而,国内目前还没有关于CXCL12-CXCR4与卵巢癌关系的相关综述,本文将从趋化因子CXCL12及其受体CXCR4,CXCL12/CXCR4轴与卵巢癌细胞系实验研究,CXCL12-CXCR4轴与卵巢癌的临床研究,CXCL12/CXCR4与卵巢癌预后,CXCL12/CXCR4与卵巢癌治疗展望等五个方面对CXCL12-CXCR4生物轴与卵巢癌的关系,及其在卵巢癌治疗中的应用展开综述。